Teva and Celltrion announced yesterday that their HERZUMA (trastuzumab-pkrb) for Injection, a biosimilar to HERCEPTIN, was available in the U.S.  The biosimilar has the same indications as the reference product, and will be priced at a Wholesale Acquisition Cost (“WAC”) that is a 10% discount to the WAC of HERCEPTIN.  The press release stated that “actual costs to individual patients and providers are anticipated to be lower than WAC” because of additional rebates and discounts.  This is the fourth trastuzumab biosimilar launched in the U.S.: Amgen launched its KANJINTI (trastuzumab-anns) in July 2019; Mylan/Biocon launched their OGIVRI (trastuzumab-dkst) in December 2019; and Pfizer launched its TRAZIMERA (trastuzumab-qyyp) in January 2020.